Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Freeman Health System
mi
from
Joplin, MO
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Freeman Health System
mi
from
Joplin, MO
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Mercy Hospital-Joplin
mi
from
Joplin, MO
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Mercy Hospital-Joplin
mi
from
Joplin, MO
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Delbert Day Cancer Institute at PCRMC
mi
from
Rolla, MO
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Delbert Day Cancer Institute at PCRMC
mi
from
Rolla, MO
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Mercy Clinic-Rolla-Cancer and Hematology
mi
from
Rolla, MO
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Mercy Clinic-Rolla-Cancer and Hematology
mi
from
Rolla, MO
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Saint Louis Cancer and Breast Institute-South City
mi
from
Saint Louis, MO
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Saint Louis Cancer and Breast Institute-South City
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Mercy Hospital Saint Louis
mi
from
Saint Louis, MO
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Mercy Hospital Saint Louis
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Mercy Hospital Springfield
mi
from
Springfield, MO
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Mercy Hospital Springfield
mi
from
Springfield, MO
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Cox Medical Center South
mi
from
Springfield, MO
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Cox Medical Center South
mi
from
Springfield, MO
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Mercy Hospital Washington
mi
from
Washington, MO
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Mercy Hospital Washington
mi
from
Washington, MO
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Nebraska Medicine-Bellevue
mi
from
Bellevue, NE
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Nebraska Medicine-Bellevue
mi
from
Bellevue, NE
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Nebraska Medicine-Village Pointe
mi
from
Omaha, NE
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Nebraska Medicine-Village Pointe
mi
from
Omaha, NE
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Comprehensive Cancer Centers of Nevada-Horizon Ridge
mi
from
Henderson, NV
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Comprehensive Cancer Centers of Nevada-Horizon Ridge
mi
from
Henderson, NV
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Desert West Surgery
mi
from
Las Vegas, NV
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Desert West Surgery
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Hope Cancer Care of Nevada-Pahrump
mi
from
Pahrump, NV
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Hope Cancer Care of Nevada-Pahrump
mi
from
Pahrump, NV
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Radiation Oncology Associates
mi
from
Reno, NV
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Radiation Oncology Associates
mi
from
Reno, NV
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Montefiore Medical Center-Einstein Campus
mi
from
Bronx, NY
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Montefiore Medical Center-Einstein Campus
mi
from
Bronx, NY
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Montefiore Medical Center-Weiler Hospital
mi
from
Bronx, NY
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Montefiore Medical Center-Weiler Hospital
mi
from
Bronx, NY
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Montefiore Medical Center - Moses Campus
mi
from
Bronx, NY
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Montefiore Medical Center - Moses Campus
mi
from
Bronx, NY
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Indu and Raj Soin Medical Center
mi
from
Beavercreek, OH
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Indu and Raj Soin Medical Center
mi
from
Beavercreek, OH
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Mercy Hospital Oklahoma City
mi
from
Oklahoma City, OK
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Mercy Hospital Oklahoma City
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Oklahoma Cancer Specialists and Research Institute-Tulsa
mi
from
Tulsa, OK
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Oklahoma Cancer Specialists and Research Institute-Tulsa
mi
from
Tulsa, OK
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Central Vermont Medical Center/National Life Cancer Treatment
mi
from
Berlin, VT
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Central Vermont Medical Center/National Life Cancer Treatment
mi
from
Berlin, VT
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Duluth Clinic Ashland
mi
from
Ashland, WI
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Duluth Clinic Ashland
mi
from
Ashland, WI
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Marshfield Clinic Cancer Center - Eau Claire
mi
from
Eau Claire, WI
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Marshfield Clinic Cancer Center - Eau Claire
mi
from
Eau Claire, WI
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Ascension Saint Michael's Hospital
mi
from
Stevens Point, WI
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Ascension Saint Michael's Hospital
mi
from
Stevens Point, WI
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
CHI Saint Vincent Cancer Center Hot Springs
mi
from
Hot Springs, AR
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
CHI Saint Vincent Cancer Center Hot Springs
mi
from
Hot Springs, AR
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Kaiser San Rafael-Gallinas
mi
from
San Rafael, CA
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Kaiser San Rafael-Gallinas
mi
from
San Rafael, CA
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Hematology and Oncology Consultants PC
mi
from
Omaha, NE
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Hematology and Oncology Consultants PC
mi
from
Omaha, NE
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
OhioHealth Marion General Hospital
mi
from
Marion, OH
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
OhioHealth Marion General Hospital
mi
from
Marion, OH
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Rhode Island Hospital
mi
from
Providence, RI
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Rhode Island Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente-Fresno
mi
from
Fresno, CA
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente-Fresno
mi
from
Fresno, CA
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Central Care Cancer Center - Bolivar
mi
from
Bolivar, MO
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Central Care Cancer Center - Bolivar
mi
from
Bolivar, MO
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
McFarland Clinic PC - Ames
mi
from
Ames, IA
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
McFarland Clinic PC - Ames
mi
from
Ames, IA
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Lakeland Hospital Niles
mi
from
Niles, MI
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Lakeland Hospital Niles
mi
from
Niles, MI
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Lakeland Medical Center Saint Joseph
mi
from
Saint Joseph, MI
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Lakeland Medical Center Saint Joseph
mi
from
Saint Joseph, MI
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Capital Region Southwest Campus
mi
from
Jefferson City, MO
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Capital Region Southwest Campus
mi
from
Jefferson City, MO
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Northwell Health- Center for Advanced Medicine
mi
from
Lake Success, NY
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Northwell Health- Center for Advanced Medicine
mi
from
Lake Success, NY
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Essentia Health Hibbing Clinic
mi
from
Hibbing, MN
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Essentia Health Hibbing Clinic
mi
from
Hibbing, MN
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Geisinger Cancer Services-Pottsville
mi
from
Pottsville, PA
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Geisinger Cancer Services-Pottsville
mi
from
Pottsville, PA
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Cancer Care Specialists of Illinois - Decatur
mi
from
Decatur, IL
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Cancer Care Specialists of Illinois - Decatur
mi
from
Decatur, IL
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Southwest Illinois Health Services LLP
mi
from
Swansea, IL
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Southwest Illinois Health Services LLP
mi
from
Swansea, IL
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
WVUH-Berkely Medical Center
mi
from
Martinsburg, WV
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
WVUH-Berkely Medical Center
mi
from
Martinsburg, WV
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Camden Clark Medical Center
mi
from
Parkersburg, WV
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Camden Clark Medical Center
mi
from
Parkersburg, WV
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Ascension Saint John Hospital
mi
from
Detroit, MI
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Ascension Saint John Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Miami Valley Hospital North
mi
from
Dayton, OH
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Miami Valley Hospital North
mi
from
Dayton, OH
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
OptumCare Cancer Care at Seven Hills
mi
from
Henderson, NV
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
OptumCare Cancer Care at Seven Hills
mi
from
Henderson, NV
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
OptumCare Cancer Care at Oakey
mi
from
Las Vegas, NV
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
OptumCare Cancer Care at Oakey
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
OptumCare Cancer Care at MountainView
mi
from
Las Vegas, NV
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
OptumCare Cancer Care at MountainView
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
OptumCare Cancer Care at Fort Apache
mi
from
Las Vegas, NV
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
OptumCare Cancer Care at Fort Apache
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
AdventHealth Infusion Center Asheville
mi
from
Asheville, NC
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
AdventHealth Infusion Center Asheville
mi
from
Asheville, NC
Click here to add this to my saved trials